

Device Companies Follow New Map To Atrial Fibrillation

November 16, 2012

Three years ago, <u>malady</u> the FDA approved Johnson & Johnson's thermocool, the first in a series of ablation catheters specifically designed to halt atrial fibrillation. Despite these advances, the long-term success rates of catheter ablation procedures remain low, opening the door for start-ups to devise new approaches.

By Mary Stuart

Read or Download Article